



The innovation engine for a better tomorrow

Q1 Earnings Call 2025

**Stock Symbol:
OTCQX:BLGO**

Safe Harbor Statement

All statements, other than statements of historical fact, included in this presentation and management's explanation and discussion of this presentation, regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management are forward-looking statements. The words "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "will," "would" and similar expressions, including graphical information, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that the expectations underlying our forward-looking statements are reasonable, these expectations may prove to be incorrect, and all of these statements are subject to risks and uncertainties. Therefore, you should not place undue reliance on our forward-looking statements. We have included important risks and uncertainties in the cautionary statements about our business in our filings with the Securities and Exchange Commission, particularly the section titled "Risk Factors" in our Form 10-K and subsequent filings. We believe these risks and uncertainties could cause actual results or events to differ materially from the forward-looking statements that we make. Should one or more of these risks and uncertainties materialize, or should underlying assumptions, projections or expectations prove incorrect, actual results, performance or financial condition may vary materially and adversely from those anticipated, estimated or expected. In the light of these risks and uncertainties, the forward-looking events and circumstances discussed in this presentation may not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements. Any forward-looking statement made by us is based only on information currently available to us and speaks only as of the date on which it is made.



Who we are

- Innovators, scientists, engineers, and entrepreneurs
- Passionate about sustainability and human health
- Driven by a mission to *make life better*



What we do

- Best-in-class solutions for cleantech problems
- Focus on problems without good solutions
- Aim for partnerships and spin-outs to capitalize on our IP

The BioLargo Innovation Engine



Investing in...



The Unseen Value of the BioLargo Portfolio



- Unmatched technologies
- Capital-conserving strategy
- Highly qualified people
- Driven for high impact



\$100M+


\$1B+

\$1B+

\$2.5B+

*These are targeted minimum future values for our portfolio companies, based on management's modeling. This analysis does not include other technologies in BioLargo's portfolio. All business plans are subject to inherent risks and market barriers to entry. *See Company's Annual and Quarterly Reports on Forms 10-K and 10-Q to understand all risks involved in the company's business plan.*

ANNUAL REVENUE RUN RATE



**Trends are not necessarily indicative of future performance, and future revenues are highly dependent on our partners' performance.*

Q1 Highlights:

Revenue

- \$3.27 million vs \$4.76 million Q1 2024 (-31%)

Net loss

- \$1.92 million vs \$0.76 million Q1 2024
- Clyra had \$1.40 million net loss compared with \$0.55 million in Q1 2024, due to continued investment in preparation for product launch
- Non-cash expenses for quarter totaled \$0.71 million

SG&A

- \$2.56 million vs \$2.23 million Q1 2024
- R&D of \$0.79 million vs \$0.78 million Q1 2024
- \$0.34 million of R&D was from Clyra


Net cash generated/used in operating activities

- (\$1.83 million) vs \$0.48 million Q1 2024

Other highlights:

- Accounts receivable of \$4.21 million at March 31, 2025 vs \$3.17 million at Dec 31, 2024 (an increase of \$1.04m)
 - We are managing the increase carefully
- Cash position: \$2.56 million at March 31, 2025, vs \$3.55 million at December 31, 2024

NET STOCKHOLDER'S EQUITY



Trends are not necessarily indicative of future performance



8
Unique Products

15+
SKUs

POOPH – Consumer pet odor product



Product marketed and sold by our partners, award-winning consumer product experts (Pooph, Inc.)



ONM receives manufacturer's margin and a royalty on sales



Business strategy: ramp up sales and sell to a major consumer products company

- ONM would receive 20% of exit





CLYRATM
Medical Technologies Inc

Clyra Medical Technologies

THE CLYRADVANTAGE

- Unmatched claims in its product categories
- FDA 510(k) cleared
- Keystone has invested over \$3 million in equipment and infrastructure in its manufacturing facilities
- Clyra has invested over \$2 million in molds, equipment and resources
- Clyra has recently formalized relationships with multiple wholesale distributors and sales agents, and has the infrastructure in place to support their efforts to sell Clyra's products to the medical industry





• BioLargo's Cellinity battery technology was created to provide a better option for battery energy storage than lithium-ion, empowering grid stability and storage of renewable energy.

Compared to lithium-ion, Cellinity is:

CELLINITY BATTERY

1

SAFER

Far safer because it has no risk of fire or explosion

2

SUSTAINABLE

More sustainable because it contains no rare earth metals or toxic chemicals

3

DURABLE

Lasts longer because its performance does not degrade with each cycle

4

EFFICIENT

Is more energy dense, making it ideal for large format energy storage



Compared to other Battery Chemistries

Specification	Lithium-ion (cobalt oxide)	Sodium-ion	Molten calcium antimony	Lead acid	Nickel cadmium	BioLargo Battery (Liquid Sodium)
Energy density (Wh/kg)	150-190	75-165	Low	30-50	45-80	552
Life cycle (down to 80% discharge)	500-1,000	2,000-6,000	No loss in discharge	200-300	1,000	No loss in discharge
Open circuit cell voltage (V)	3.7	~2.1	~2.5	2	1.2	4.2
Operating temperature (°C)	0 to 45	-20 to 40	~500	-20 to 50	-20 to 65	120 to 250
Self-discharge (%/month)	<10%	Negligible		5%	20%	0
Safety considerations	<ul style="list-style-type: none"> Serious fires can occur, protection circuit mandatory Thermal runaway possible 	No serious risks	<ul style="list-style-type: none"> Jacket is very hot (minor safety concern) Not to be shaken 	<ul style="list-style-type: none"> Very toxic 	<ul style="list-style-type: none"> Very toxic Fuse protection required 	<ul style="list-style-type: none"> NO THERMAL RUNAWAY Insulated for high temperatures
Toxicity considerations	Low	Low risk	Contains antimony (toxic)	Very toxic	Very toxic	Low risk
Materials	Scarce	Earth-abundant	Earth-abundant	Diverse supply	Cadmium rare	Earth-abundant

Initially Targeting Two BESS Module Sizes:


1-2 MWh



~25 KWh




Commercialization Pathway and Valuation Roadmap





***A Broad-Spectrum,
Low-Waste PFAS
Capture Technology
and Efficient
Destruction***





**~1-2 lbs of
concentrate**


Why waste production matters

**Waste generated from treating
20,000 gallons of PFAS
contaminated water**

Granular Activated Carbon Treatment



**20-40,000 lbs of
spent carbon**



Q1 updates


- AEC system ready to ship to New Jersey project
- Target August/September installation
- Case study demonstrating 80% lifecycle cost savings of AEC process vs GAC for treating water
- On April 28, 2025 the EPA released a press release reaffirming the agency's commitment to the reduction of PFAS in the environment

Cost advantage when treating drinking water



Why?

- Far less treatment material needs to be replaced over time compared to GAC systems
- Far less waste product generated in the course of water treatment
- PFAS-laden waste generated in the course of water treatment is expensive



The BioLargo Family of Companies

BioLargo, Inc. is a sustainable science, technology & full-service environmental engineering company that **makes life better** by delivering world-class products and services across a broad range of industries, with a drive to deliver clean water, clean air, and advanced antimicrobials for healthcare.



**OTCQX:
BLGO**

Contact:

Dennis Calvert

President & CEO

BioLargo, Inc.

14921 Chestnut St.

Westminister, CA 92683

(888) 400-2863

dc@BioLargo.com

www.BioLargo.com